{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:05:01Z","timestamp":1793271901947,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00213-025-06773-3","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T18:08:52Z","timestamp":1743185332000},"page":"1693-1711","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of efficacy and safety of dual orexin receptor antagonists lemborexant and daridorexant for the treatment of insomnia: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"242","author":[{"given":"Ming","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peilu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiong","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-2221","authenticated-orcid":false,"given":"Guohui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"issue":"4","key":"6773_CR1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s40120-024-00622-9","volume":"13","author":"V Arnold","year":"2024","unstructured":"Arnold V, Ancoli-Israel S, Dang-Vu TT et al (2024) Efficacy of lemborexant in adults >\/= 65 years of age with insomnia disorder. Neurol Ther 13(4):1081\u20131098. https:\/\/doi.org\/10.1007\/s40120-024-00622-9","journal-title":"Neurol Ther"},{"issue":"12","key":"6773_CR2","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1161\/hypertensionaha.122.19796","volume":"79","author":"JA Bigalke","year":"2022","unstructured":"Bigalke JA, Shan Z, Carter JR (2022) Orexin, sleep, sympathetic neural activity, and cardiovascular Function. Hypertension 79(12):2643\u20132655. https:\/\/doi.org\/10.1161\/hypertensionaha.122.19796","journal-title":"Hypertension"},{"issue":"3","key":"6773_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1080\/00325481.2022.2049553","volume":"134","author":"C Chepke","year":"2022","unstructured":"Chepke C, Jain R, Rosenberg R et al (2022) Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder. Postgrad Med 134(3):316\u2013325. https:\/\/doi.org\/10.1080\/00325481.2022.2049553","journal-title":"Postgrad Med"},{"key":"6773_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4088\/JCP.20m13795","volume":"82","author":"L Citrome","year":"2021","unstructured":"Citrome L, Juday T, Frech F et al (2021) Lemborexant for the treatment of insomnia: direct and indirect comparisons with other hypnotics using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Clin Psychiatry 82:82. https:\/\/doi.org\/10.4088\/JCP.20m13795","journal-title":"J Clin Psychiatry"},{"key":"6773_CR5","doi-asserted-by":"publisher","unstructured":"Citrome L, Juday T R,Lundwall C (2023) Lemborexant and Daridorexant for the Treatment of Insomnia: An Indirect Comparison Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed. J Clin Psychiatry 84(6). https:\/\/doi.org\/10.4088\/JCP.23m14851.","DOI":"10.4088\/JCP.23m14851"},{"issue":"8","key":"6773_CR6","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.5694\/mja13.10718","volume":"199","author":"D Cunnington","year":"2013","unstructured":"Cunnington D, Junge MF, Fernando AT (2013) Insomnia: prevalence, consequences and effective treatment. Med J Aust 199(8):S36-40. https:\/\/doi.org\/10.5694\/mja13.10718","journal-title":"Med J Aust"},{"issue":"3","key":"6773_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ana.25680","volume":"87","author":"Y Dauvilliers","year":"2020","unstructured":"Dauvilliers Y, Zammit G, Fietze I et al (2020) Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder. Ann Neurol 87(3):347\u2013356. https:\/\/doi.org\/10.1002\/ana.25680","journal-title":"Ann Neurol"},{"issue":"7","key":"6773_CR8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40263-023-01020-9","volume":"37","author":"T Di Marco","year":"2023","unstructured":"Di Marco T, Scammell TE, Meinel M et al (2023) Number, duration, and distribution of wake bouts in patients with insomnia disorder: effect of daridorexant and zolpidem. CNS Drugs 37(7):639\u2013653. https:\/\/doi.org\/10.1007\/s40263-023-01020-9","journal-title":"CNS Drugs"},{"issue":"10","key":"6773_CR9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s40266-022-00977-4","volume":"39","author":"I Fietze","year":"2022","unstructured":"Fietze I, Bassetti CLA, Mayleben DW et al (2022) Efficacy and safety of daridorexant in older and younger adults with insomnia disorder: a secondary analysis of a randomised placebo-controlled trial. Drugs Aging 39(10):795\u2013810. https:\/\/doi.org\/10.1007\/s40266-022-00977-4","journal-title":"Drugs Aging"},{"key":"6773_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.euroneuro.2024.01.011","volume":"81","author":"M Fornaro","year":"2024","unstructured":"Fornaro M, Caiazza C, Rossano F et al (2024) Residual effects of medications for sleep disorders on driving performance: a systematic review and network meta-analysis of randomized controlled trials: NMA driving and hypnotics. Eur Neuropsychopharmacol 81:53\u201363. https:\/\/doi.org\/10.1016\/j.euroneuro.2024.01.011","journal-title":"Eur Neuropsychopharmacol"},{"key":"6773_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.sleep.2023.11.033","volume":"113","author":"M Fornaro","year":"2024","unstructured":"Fornaro M, Caiazza C, De Simone G et al (2024) Insomnia and related mental health conditions: essential neurobiological underpinnings towards reduced polypharmacy utilization rates. Sleep Med 113:198\u2013214. https:\/\/doi.org\/10.1016\/j.sleep.2023.11.033","journal-title":"Sleep Med"},{"issue":"3","key":"6773_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/inthealth\/ihac060","volume":"15","author":"TG Haile","year":"2023","unstructured":"Haile TG, Mariye T, Tadesse DB et al (2023) Prevalence of hypertension among type 2 diabetes mellitus patients in Ethiopia: a systematic review and meta-analysis. Int Health 15(3):235\u2013241. https:\/\/doi.org\/10.1093\/inthealth\/ihac060","journal-title":"Int Health"},{"key":"6773_CR13","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"issue":"5","key":"6773_CR14","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.5664\/jcsm.9148","volume":"17","author":"Y Inoue","year":"2021","unstructured":"Inoue Y, Watanabe T, Takashima S et al (2021) Efficacy and safety of lemborexant in adults with insomnia: comparing Japanese and non-Japanese subgroups from the global, phase 3, randomized, double-blind, placebo-controlled SUNRISE 2 study. J Clin Sleep Med 17(5):1067\u20131074. https:\/\/doi.org\/10.5664\/jcsm.9148","journal-title":"J Clin Sleep Med"},{"issue":"3","key":"6773_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.5664\/jcsm.10378","volume":"19","author":"Y Inoue","year":"2023","unstructured":"Inoue Y, Nishida M, Kubota N et al (2023) Comparison of the treatment effectiveness between lemborexant and zolpidem tartrate extended-release for insomnia disorder subtypes defined based on polysomnographic findings. J Clin Sleep Med 19(3):519\u2013528. https:\/\/doi.org\/10.5664\/jcsm.10378","journal-title":"J Clin Sleep Med"},{"issue":"3","key":"6773_CR16","doi-asserted-by":"publisher","first-page":"ITC33","DOI":"10.7326\/aitc202103160","volume":"174","author":"EL Sutton","year":"2021","unstructured":"Sutton EL (2021) Insomnia. Ann Intern Med 174(3):ITC33\u2013ITC48. https:\/\/doi.org\/10.7326\/aitc202103160","journal-title":"Ann Intern Med"},{"issue":"9","key":"6773_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa123","volume":"43","author":"M K\u00e4rpp\u00e4","year":"2020","unstructured":"K\u00e4rpp\u00e4 M, Yardley J, Pinner K et al (2020) Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep 43(9):zsaa123. https:\/\/doi.org\/10.1093\/sleep\/zsaa123","journal-title":"Sleep"},{"key":"6773_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jpsychires.2020.05.025","volume":"128","author":"T Kishi","year":"2020","unstructured":"Kishi T, Nomura I, Matsuda Y et al (2020) Lemborexant vs suvorexant for insomnia: a systematic review and network meta-analysis. J Psychiatr Res 128:68\u201374. https:\/\/doi.org\/10.1016\/j.jpsychires.2020.05.025","journal-title":"J Psychiatr Res"},{"issue":"1","key":"6773_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40263-022-00980-8","volume":"37","author":"D Kunz","year":"2023","unstructured":"Kunz D, Dauvilliers Y, Benes H et al (2023) Long-term safety and tolerability of daridorexant in patients with insomnia disorder. CNS Drugs 37(1):93\u2013106. https:\/\/doi.org\/10.1007\/s40263-022-00980-8","journal-title":"CNS Drugs"},{"issue":"5","key":"6773_CR20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","volume":"82","author":"A Markham","year":"2022","unstructured":"Markham A (2022) Daridorexant: first approval. Drugs 82(5):601\u2013607. https:\/\/doi.org\/10.1007\/s40265-022-01699-y","journal-title":"Drugs"},{"issue":"2","key":"6773_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","volume":"21","author":"E Mignot","year":"2022","unstructured":"Mignot E, Mayleben D, Fietze I et al (2022) Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol 21(2):125\u2013139. https:\/\/doi.org\/10.1016\/S1474-4422(21)00436-1","journal-title":"Lancet Neurol"},{"issue":"6","key":"6773_CR22","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.5664\/jcsm.9150","volume":"17","author":"M Moline","year":"2021","unstructured":"Moline M, Zammit G, Cheng JY et al (2021) Comparison of the effect of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults with insomnia disorder. J Clin Sleep Med 17(6):1167\u20131174. https:\/\/doi.org\/10.5664\/jcsm.9150","journal-title":"J Clin Sleep Med"},{"issue":"11","key":"6773_CR23","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.5664\/jcsm.6800","volume":"13","author":"P Murphy","year":"2017","unstructured":"Murphy P, Moline M, Mayleben D et al (2017) Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a bayesian, adaptive, randomized, double-blind. Placebo-Control Study J Clin Sleep Med 13(11):1289\u20131299. https:\/\/doi.org\/10.5664\/jcsm.6800","journal-title":"Placebo-Control Study J Clin Sleep Med"},{"issue":"2","key":"6773_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsad293","volume":"47","author":"HJ Na","year":"2024","unstructured":"Na HJ, Jeon N, Staatz CE et al (2024) Clinical safety and narcolepsy-like symptoms of dual orexin receptor antagonists in patients with insomnia: a systematic review and meta-analysis. Sleep 47(2):zsad293. https:\/\/doi.org\/10.1093\/sleep\/zsad293","journal-title":"Sleep"},{"key":"6773_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"10357","key":"6773_CR26","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/s0140-6736(22)00879-0","volume":"400","author":"ML Perlis","year":"2022","unstructured":"Perlis ML, Posner D, Riemann D et al (2022) Insomnia. Lancet 400(10357):1047\u20131060. https:\/\/doi.org\/10.1016\/s0140-6736(22)00879-0","journal-title":"Insomnia. Lancet"},{"issue":"4","key":"6773_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13665","volume":"31","author":"F Pizza","year":"2022","unstructured":"Pizza F, Barateau L, Dauvilliers Y et al (2022) The orexin story, sleep and sleep disturbances. J Sleep Res 31(4):e13665. https:\/\/doi.org\/10.1111\/jsr.13665","journal-title":"J Sleep Res"},{"issue":"6","key":"6773_CR28","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/jsr.12594","volume":"26","author":"D Riemann","year":"2017","unstructured":"Riemann D, Baglioni C, Bassetti C et al (2017) European guideline for the diagnosis and treatment of insomnia. J Sleep Res 26(6):675\u2013700. https:\/\/doi.org\/10.1111\/jsr.12594","journal-title":"J Sleep Res"},{"issue":"4","key":"6773_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13604","volume":"31","author":"D Riemann","year":"2022","unstructured":"Riemann D, Benz F, Dressle RJ et al (2022) Insomnia disorder: state of the science and challenges for the future. J Sleep Res 31(4):e13604. https:\/\/doi.org\/10.1111\/jsr.13604","journal-title":"J Sleep Res"},{"issue":"6","key":"6773_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.14035","volume":"32","author":"D Riemann","year":"2023","unstructured":"Riemann D, Espie CA, Altena E et al (2023) The European Insomnia Guideline: an update on the diagnosis and treatment of insomnia 2023. J Sleep Res 32(6):e14035. https:\/\/doi.org\/10.1111\/jsr.14035","journal-title":"J Sleep Res"},{"issue":"12","key":"6773_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18254","volume":"2","author":"R Rosenberg","year":"2019","unstructured":"Rosenberg R, Murphy P, Zammit G et al (2019) Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open 2(12):e1918254. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.18254","journal-title":"JAMA Netw Open"},{"key":"6773_CR32","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.sleep.2022.01.024","volume":"90","author":"T Roth","year":"2022","unstructured":"Roth T, Rosenberg R, Morin CM et al (2022) Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorder. Sleep Med 90:249\u2013257. https:\/\/doi.org\/10.1016\/j.sleep.2022.01.024","journal-title":"Sleep Med"},{"issue":"4","key":"6773_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40265-020-01276-1","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ (2020) Lemborexant: first approval. Drugs 80(4):425\u2013432. https:\/\/doi.org\/10.1007\/s40265-020-01276-1","journal-title":"Drugs"},{"issue":"5","key":"6773_CR34","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s40120-023-00530-4","volume":"12","author":"Z Shen","year":"2023","unstructured":"Shen Z, Bao N, Tang M et al (2023) Tenecteplase vs. alteplase for intravenous thrombolytic therapy of acute ischemic stroke: a systematic review and meta-analysis. Neurol Ther 12(5):1553\u20131572. https:\/\/doi.org\/10.1007\/s40120-023-00530-4","journal-title":"Neurol Ther"},{"issue":"4","key":"6773_CR35","doi-asserted-by":"publisher","first-page":"603","DOI":"10.5664\/jcsm.10946","volume":"20","author":"M Tachibana","year":"2024","unstructured":"Tachibana M, Kanahara N, Oda Y et al (2024) A retrospective clinical practice study comparing the usefulness of dual-orexin receptor antagonists and a melatonin receptor agonist in patients switching from long-term benzodiazepine receptor agonists. J Clin Sleep Med 20(4):603\u2013613. https:\/\/doi.org\/10.5664\/jcsm.10946","journal-title":"J Clin Sleep Med"},{"issue":"8","key":"6773_CR36","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/gme.0000000000002209","volume":"30","author":"M Terauchi","year":"2023","unstructured":"Terauchi M, Cheng JY, Yardley J et al (2023) Efficacy and safety of lemborexant in midlife women with insomnia disorder. Menopause 30(8):839\u2013848. https:\/\/doi.org\/10.1097\/gme.0000000000002209","journal-title":"Menopause"},{"issue":"2","key":"6773_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/10600280211008492","volume":"56","author":"K Waters","year":"2022","unstructured":"Waters K (2022) Review of the efficacy and safety of lemborexant, a dual receptor orexin antagonist (DORA), in the treatment of adults with insomnia disorder. Ann Pharmacother 56(2):213\u2013221. https:\/\/doi.org\/10.1177\/10600280211008492","journal-title":"Ann Pharmacother"},{"issue":"10","key":"6773_CR38","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11920-022-01357-w","volume":"24","author":"X Wu","year":"2022","unstructured":"Wu X, Xue T, Chen Z et al (2022) Orexin receptor antagonists and insomnia. Curr Psychiatry Rep 24(10):509\u2013521. https:\/\/doi.org\/10.1007\/s11920-022-01357-w","journal-title":"Curr Psychiatry Rep"},{"key":"6773_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1338110","volume":"15","author":"Y Xiong","year":"2024","unstructured":"Xiong Y, Zhong Q, Zhang Y et al (2024) The association between circadian syndrome and chronic kidney disease in an aging population: a 4-year follow-up study. Front Endocrinol (Lausanne) 15:1338110. https:\/\/doi.org\/10.3389\/fendo.2024.1338110","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"15","key":"6773_CR40","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s40265-014-0294-5","volume":"74","author":"LP Yang","year":"2014","unstructured":"Yang LP (2014) Suvorexant: first global approval. Drugs 74(15):1817\u20131822. https:\/\/doi.org\/10.1007\/s40265-014-0294-5","journal-title":"Drugs"},{"key":"6773_CR41","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.sleep.2021.01.048","volume":"80","author":"J Yardley","year":"2021","unstructured":"Yardley J, K\u00e4rpp\u00e4 M, Inoue Y et al (2021) Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial. Sleep Med 80:333\u2013342. https:\/\/doi.org\/10.1016\/j.sleep.2021.01.048","journal-title":"Sleep Med"},{"key":"6773_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.sleep.2023.07.023","volume":"110","author":"J Yardley","year":"2023","unstructured":"Yardley J, Inoue Y, Pinner K et al (2023) Efficacy and safety of lemborexant in subjects previously treated with placebo for 6 months in a randomized phase 3 study. Sleep Med 110:111\u2013119. https:\/\/doi.org\/10.1016\/j.sleep.2023.07.023","journal-title":"Sleep Med"},{"issue":"2","key":"6773_CR43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cger.2018.01.008","volume":"34","author":"K Yaremchuk","year":"2018","unstructured":"Yaremchuk K (2018) Sleep disorders in the elderly. Clin Geriatr Med 34(2):205\u2013216. https:\/\/doi.org\/10.1016\/j.cger.2018.01.008","journal-title":"Clin Geriatr Med"},{"issue":"21","key":"6773_CR44","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/wnl.0000000000009475","volume":"94","author":"G Zammit","year":"2020","unstructured":"Zammit G, Dauvilliers Y, Pain S et al (2020) Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology 94(21):e2222\u2013e2232. https:\/\/doi.org\/10.1212\/wnl.0000000000009475","journal-title":"Neurology"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06773-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-025-06773-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06773-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T06:44:44Z","timestamp":1753425884000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-025-06773-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6773"],"URL":"https:\/\/doi.org\/10.1007\/s00213-025-06773-3","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no conflicts of interest to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}